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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a major cause of morbidity and mortality underscoring the need for
safe and effective chemopreventive strategies. Targeting epidermal growth factor receptor (EGFR) is attractive in that it is an
early critical event in HNSCC pathogenesis. However, current agents lack efficacy or have unacceptable toxicity. Several
groups have demonstrated that the over-the-counter medication, polyethylene glycol (PEG) has remarkable chemopre-
ventive efficacy against colon carcinogenesis. Importantly, we reported that this effect is mediated through EGFR
internalization/degradation. In the current study, we investigated the chemopreventive efficacy of this agent against
HNSCC, using both the well validated animal model 4-NQO (4-nitroquinoline 1-oxide) rat model and cell culture with the
human HNSCC cell line SCC-25. We demonstrated that daily topical application of 10% PEG-8000 in the oral cavity (tongue
and cavity wall) post 4NQO initiation resulted in a significant reduction in tumor burden (both, tumor size and tumors/
tumor bearing rat) without any evidence of toxicity. Immunohistochemical studies depicted decreased proliferation
(number of Ki67-positive cells) and reduced expression of EGFR and its downstream effectors cyclin D1 in the tongue
mucosa of 4NQO-rats treated with PEG. We showed that EGFR was also markedly downregulated in SCC-25 cells by PEG-
8000 with a concomitant induction of G1-S phase cell-cycle arrest, which was potentially mediated through upregulated
p21
cip1/waf1. In conclusion, we demonstrate, for the first time, that PEG has promising efficacy and safety as a
chemopreventive efficacy against oral carcinogenesis.
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Introduction
Squamous cell carcinoma of the head and neck region
(HNSCC) is the sixth most prevalent cancer worldwide, account-
ing for 3% of all cancers [1]. In 2010, in the US alone there were
an estimated 49,000 new HNSCC cases and 11,500 HNSCC
related-deaths [2]. Importantly, these numbers do not take into
account severe morbidity from the facial disfigurement and
aerodigestive dysfunction associated with surgery/radiotherapy.
Prevention of this malignancy, therefore, represents a major
healthcare imperative. Modifications of certain life-style risk
factors would be ideal but difficult to achieve despite major public
health efforts against tobacco use (both smoked and chewed), betel
nut chewing, alcohol consumption and HPV (infection) status.
Therefore, interest has focused on chemoprevention given that
the at-risk groups are well defined for primary prevention efforts;
those with early neoplastic transformation (oral leukoplakia) which
can be identified by a standard physical exam. An equally
important application would be secondary chemoprevention
(preventing second primaries HNSCC in patients with a previous
history of cancer).
It has been noted that even after successful tumor resection
(histopathologically clear margins); ,20% patients may still have
recurrence of HNSCC at a different site (about 2% per year) [3].
This has largely been attributed to ‘‘field cancerization’’ et [4].
Indeed, classic studies have suggested that several mutational
events in the microscopically normal mucosa can be predictive of
recurrent HNSCC and overall survival [5]. This ‘‘condemned
mucosa’’ concept is robust not only for prevention of recurrence
(secondary prevention) but also presents a potential target for
primary chemoprevention (patients without cancer but having
premalignant lesions).
Thus, finding molecular targets in the premalignant mucosa has
been an overarching theme in HNSCC prevention with epidermal
growth factor receptor (EGFR) receiving some attention. EGFR is
a critical early event in HNSCC and is overexpressed in .80% of
HNSCC. EGFR overexpression and increased copy number in
oral premalignant lesions is an excellent predictor of the risk of
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been found in histologically normal mucosa from HNSCC patients
indicating that altered EGFR signaling contributes to the field
cancerization seen in these patients [7]. Importantly, targeting
EGFR is a stalwart for anti-HNSCC therapies underscoring the
importance of this pathway. However, as with most other
molecular-targeted drugs, the major issues concerning the use of
anti-EGFR agents (monoclonal antibodies, small molecule inhib-
itors, etc) for chemoprevention are their high costs for prolonged
use and associated toxicity, especially given that the majority of
patients offered chemopreventive agents do not have cancer.
Therefore, finding an inexpensive, well tolerated mechanism to
target EGFR in oral mucosa would be a major step forward in
HNSCC chemoprevention effort.
Our group has been exploring the over-the-counter laxative
polyethylene glycol (PEG) for its remarkable potency at downreg-
ulating EGFR and thus providing a potential explanation for its
colon cancer chemopreventive efficacy (documented by several
groups in a number of pre-clinical models) [8,9,10,11,12,13].
From a mechanistic point of view, we observed that PEG resulted
in rapid internalization of membrane bound EGFR with
concomitant proteosomal degradation. This leads to decreased
cyclin D1 and SNAIL (implicated in both colorectal cancer and
HNSCC) thus transducing the anti-neoplastic effects of PEG [13].
We therefore hypothesized that topical PEG may be an effective
chemopreventive agent against HNSCC. For these studies we used
a well-validated carcinogen, 4-Nitroquinoline 1-oxide (4-NQO)-
treated rat model of HNSCC and squamous cancer cell line,
SCC25 cells. Given the concern that PEG may confound the effect
with a direct carcinogen-oral mucosal interaction, we used a post-
initiation design using tumor size and multiplicity as our primary
endpoints and the well validated intermediate biomarkers of
proliferation as a secondary endpoint. We, herein for the first time,
demonstrate that daily topical oral application of PEG-8000 for a
short interval significantly decreased the oral tumor burden (both
tumor size and number).
Materials and Methods
Animals Studies and Tumor Induction
All animal protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of NorthShore
University HealthSystem (IACUC Assurance # A3444-01;
protocol # 07-230). Twenty-four male Fisher rats (F 344; 150–
200 g; Harlan, Indianapolis, IN) were housed in a climate
controlled environment (25uC temperature, 60% humidity and a
12 h light/day cycle). Sixteen animals were provided ad libitum rat
chow and drinking water supplemented with 4-nitroquinoline 1-
oxide (4NQO; 20 ppm; Sigma Chemicals). Freshly made 4NQO
supplemented water was dispensed to rats in light opaque bottles
that were replenished two times a week. The remaining 8 rats were
provided clean drinking water (control group). After 14 weeks, the
4NQO supplemented water was replaced with regular water and
the rats were randomized into two treatment groups. The first
group (8 rats) received a daily topical application of 10% (W/V)
PEG-8000 (the dosage/formulation effective in colon cancer
chemoprevention) by painting the buccal floor/roof of the rat oral
cavity using a sable brush (#4) for up to 3–4 minutes. For these
treatments, the rats were mildly sedated in a well regulated
isoflurane/oxygen anesthetic chamber. The second group (8 rats),
serving as the control, was sham painted with the brush dipped in
saline only. This regimen was continued for 14 additional weeks.
At necropsy, rat tongues were excised, and subjected to
macroscopic tumor assessment. The tongue sections were sliced,
formalin fixed, paraffin embedded, sectioned and subjected to
histological and immunohistochemical processing.
Tumor Count and Volume
The dissected tongues were examined for the presence of overt
tumors. Total number of tumors (.0.2 cm) on each tongue were
counted and the tumor volume (size) was measured according to
the formula width 6 length 6 height 6 p/6 [14]. Histological
evaluations for the presence of epithelial atypia and dysplasia in
the uninvolved tongue tissue were performed after staining with
hematoxylin and eosin.
Immunohistochemical (IHC) Analysis
The tongue sections were subjected to IHC analysis to
determine the effect of PEG on the expression of proliferation
markers Ki67, EGFR and Cyclin D1. Four micron paraffin-
embedded sections were mounted on Superfrost
+ slides (Vector
Laboratories, Burlingame, CA) and deparaffinized first by baking
at 55–60uC for 1 hour and then subjecting to two 5 minute washes
in xylene. The tissue sections were then hydrated in graded series
of ethanol rinses. The epitope retrieval was performed by
subjecting the tissue slides to pressure microwaving (NordicWare,
Minneapolis, MN) in antigen unmasking solution (Vector Labo-
ratories). Endogenous peroxide activity was quenched by treating
with 3% H2O2 in methanol for 10 min and the nonspecific
binding was blocked by incubating the tissue sections with 5%
horse serum for 1 hour at room temperature. Sections were then
incubated at 4uC for 4–6 hours with primary antibodies [anti-Ki67
(1:250; AbCam, Cambridge, MA), anti-EGFR (1:200; Santa Cruz
Biotechnology, Santa Cruz, CA) and anti-Cyclin D1 (1:100; Cell
Signaling Technology, Danvers, MA)], followed by appropriate
biotinylated secondary antibodies. The antigen-antibody com-
plexes were detected with the Vectastatin Elite ABC kit (Vector
Laboratories) using 3, 39 –diaminobenzidine (DAB) as chromagen
(Vector Laboratories). For negative controls, sections were
processed in the absence of the primary antibodies. Specimens
were counterstained in Gill’s hematoxylin solution and the blue
color stabilized by a 20 second wash in saturated lithium
carbonate (1 g/100 ml). IHC was scored by the pathologist
(CW) with no prior knowledge of the treatment plan. A semi-
quantitative scale was used to evaluate immunoreactivity of basal
squamous epithelial cells. The extent of staining was graded and
scored as 0, negative staining; 1+, ,10% reactivity, 2+10–50%
reactive, and 3+ for .50% positive reactivity [15].
Cell Culture
SCC-25 cells were obtained from American Type Tissue
Culture (ATCC), Rockville, MD. These are poorly differentiated
squamous cells obtained from human tongue. The identity and
quality of these cells were authenticated by ATCC. The cells were
cultured in DMEM/F-12 media (containing 2.5 mM L-glutamine,
15 mM HEPES, 0.5 mM sodium pyruvate, and 1200 mg/L
sodium bicarbonate) supplemented with 400 ng/ml of hydrocor-
tisone (Sigma/Aldrich), 10% FBS (ATCC), and 0.5% Pen/Strep
(ATCC). To assess the effect of PEG, these cells were treated with
either PEG-8000 or vehicle (PBS) for 24 h. Cells were then
harvested and subjected to western blot and flow cytometric
analyses.
Cell Proliferation Assay
Cell number was assessed by WST-1 (4-[3-(4-iodophenyl)-2-(4-
nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene disulfonate) assay ac-
cording to the manufacturer’s instructions (Roche Diagnostics,
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PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e38047Figure 1. Effect of topical oral application of PEG-8000 on the initiation and progression of 4NQO-induced oral cancer –Fisher rats
were provided 4NQO (20 ppm) in drinking water for 14 weeks before switching to regular water and randomizing into two groups.
The first group received a daily (3–4 minute) topical application of 10% PEG-8000 via oral painting and the second group was sham painted (PEG-
control group). This regimen was continued for 14 additional weeks before euthanization. The rats were euthanized after 14 weeks and the oral cavity
subjected to macroscopic tumor assessment of total tumors ($0.2 cm). As shown, 4NQO-treated rats developed multiple large tumors in the oral
cavity mostly originating from tongue and few from the wall of the oral cavity. PEG reduced the overall tumor number (tumors/tumor bearing rat)
(p=0.05) and the growth of tumors (tumor volume) compared to their age-matched counterparts (p=0.02). The tumor volume (size) was measured
according to the formula width 6length 6height 6p/6.
doi:10.1371/journal.pone.0038047.g001
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plates in a final volume of 100 ml and then incubated with 10 mlo f
the WST-1 reagent at 37uC for 30 min in a humidified 5% CO2
incubator. Conversion of tetrazolium salt into formazan was
determined spectrophotometrically at 440 nm absorbance (Mo-
lecular Devices, Sunnyvale, CA).
Cell Cycle Analysis
SCC-25 cells were incubated with vehicle (phosphate buffered
saline; PBS) or 10% PEG in a humidified 5% CO2 incubator at
37uC for 24 h. The cells were subsequently washed in PBS/bovine
serum albumin (BSA), trypsinized, resuspended in fresh PBS/BSA
and fixed in 70% ethanol at -20uC for 30 min. After 2 washes, the
cells were incubated for 3 h (at room temperature) in PBS/BSA
solution containing propidium iodide (PI; 40-mg/ml, Sigma) and
RNase A (200 mg/ml; Sigma). The cells were subjected to DNA
content measurement using flow cytometry (Becton Dickinson
Labware). The data was expressed as percentage of cells in Go–G1
through G2-M populations and CellQuest 3.1 software program
was used for the development of DNA content frequency
histograms.
Western Blot Analysis
Western blotting was applied using standard techniques. Briefly,
30 mg protein was subjected to SDS-PAGE, transferred to
polyvinylidene difluoride membranes (Amersham Pharmacia,
Piscataway, NJ), blocked with 5% blotto and probed with specific
antibodies including proliferating cell nuclear antigen (PCNA),
P21
cip1/waf1, Cyclin D1, epidermal growth factor receptor (EGFR).
Xerograms were developed with enhanced chemiluminescence
(Santa Cruz Biotechnology). Images were acquired via UVP Bio-
imaging Systems and analyzed using Labworks 4.6 software.
Uniformity in protein loading was achieved by normalization after
probing membranes with anti-b-actin (1:1000).
Statistical Methods
Values were expressed as mean + SE as indicated. Quantitative
densitometry values were compared by paired Student’s test.
Differences with p,0.05 were considered statistically significant.
Results
PEG Inhibits 4NQO-induced Oral Tumor Initiation and
Progression
The rat 4NQO-induced oral carcinogenesis model is a routinely
used model for HNSCC chemoprevention studies which shares a
number of characteristics with human HNSCC carcinogenesis, in
terms of multi-step molecular events and sequential changes in the
histopathological features of the oral cavity mucosa [16,17]. One
of the other advantages of this model is the relatively high
specificity toward head and neck tumors, as well as minimal
debilitating effect on the general health of the rats. As shown in
Figure 1 (A), at necropsy (14 weeks after the end of carcinogen
treatment), 4NQO-treated rats developed multiple large tumors in
the oral cavity, mostly originating from tongue and some from the
oropharyngeal mucosa. Administration of PEG-8000 for 14 weeks
after completing 4NQO treatment demonstrated two significant
changes: 1) PEG-8000 treated rats developed significantly smaller
tumors (tumor volume) than their age- and 4NQO treatment-
matched counterparts (,58% decrease; p=0.02); 2) the overall
tumor number (tumors/tumor bearing rat) in PEG-8000 treated
rats was also lower than age- and 4NQO treatment-matched rats
which did not receive PEG-8000 at any point (,25% decrease;
p=0.05) (Figure 1B). These results imply that PEG-8000
application can effectively reduce formation of new tumors
(inhibition of initiation) as well as halt the progression of pre-
existing tumors toward advanced HNSCC (inhibition of progres-
sion).
PEG Suppresses Premalignant Epithelial
Hyperproliferation
A precise temporal and spatial regulation of the diffuse cellular
proliferation is an important characteristic of early-stage HNSCC
carcinogenesis, and serves as an important tool for assessing
chemopreventive effectiveness of agents. In 4NQO-treated rat
model of HNSCC carcinogenesis, generalized cellular hyperpro-
liferation in the tongue epithelium has previously been reported
[18]. Microscopic evaluation of the mucosa in 4NQO-treated rats
revealed many localized regions of mild to moderate epithelial
dysplasia in morphologically normal tongue and oral mucosa that
were normalized by PEG (Figure 2A). To further study the effects
of PEG-8000 application on proliferation in the tongue/oral
mucosa of 4NQO-treated rats, we examined the immunohisto-
chemical expression of nuclear antigen Ki67, a well-defined
marker of proliferation. For this, a total of 1000 epithelial cells
were evaluated in 6–7 fields at 400 6 magnification and all the
values were used for the labeling indices. As shown in Figure 2A
and B, 4NQO-treatment significantly increased the proliferation
in morphologically normal tongue mucosa as depicted (number of
Ki67-labelled epithelial cells/per optical field: 30+8 in 4NQO-
treatment group vs. 14+6 in matched controls; p,0.01). Topical
application of PEG-8000 dramatically normalized proliferation
indices in 4NQO-treated rats (number of Ki67-labelled epithelial
cells/per optical field: 30+8 in rats treated with 4NQO-alone vs.
17+4 in 4NQO-treated rats treated with PEG-8000; ,43%
reduction; p,0.01). In the mucosal epithelium of 4NQO-treated
rats, as opposed to normal squamous epithelium where prolifer-
ation is limited to the basal compartment, the proliferation zone
extended to the supra-basal compartment of the stratified
squamous tongue epithelium. However, PEG-8000 application
contained the proliferative zone back to the basal compartment of
the stratified squamous epithelia, indicating strong anti-prolifera-
tive effects of this topical agent.
PEG Downregulates Tongue Mucosal EGFR and Cyclin D1
Expression in 4 NQO-treated Rats
EGFR overexpression in the premalignant head and neck
lesions is correlated with the increased risk of progression to
HNSCC and poor survival [19,20]. Modulating EGFR expression
can therefore serve as the key element of a chemopreventive
strategy. Several groups, including ours have previously shown
that anti-proliferative and chemopreventive effects of PEG against
colorectal carcinogenesis are EGFR-mediated, as administration
of PEG-gavages in carcinogen treated rats significantly reduced
proliferation in colonic mucosa through downregulation of EGFR
expression [13]. We therefore, investigated if a similar mechanism
was implicated in the chemopreventive actions of topical PEG-
8000 against HNSCC. The tongue sections were formalin fixed
and examined by immunostaining to assess changes in the
expression levels of EGFR. As shown in Figure 3A and B, topical
application of PEG-8000 significantly lowered the intensity as well
as the number of areas overexpressing EGFR in 4NQO-treated
rats where baseline EGFR expression was much higher than the
tongue/oral mucosa of healthy control rats. This implicates
downregulation of EGFR as one of the potential mechanisms for
PEG-induced chemoprevention of HNSCC. We further demon-
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38047Figure 2. Effect of topical oral application of PEG-8000 on the premalignant epithelial hyperproliferation – To evaluate
histopathological grading of the oral/tongue tissue, the formalin fixed sections were paraffin embedded, sectioned and subjected
to H&E staining. As shown (top Panel; Figure 2A), 4NQO-treated rat sections revealed many localized regions of mild to moderate epithelial
dysplasia in morphologically normal appearing mucosa that was normalized by PEG [higher magnification (636; cropped image) insets demonstrate
the presence of mitotic figures in the 4 NQO-treated group alone]. To further study the effects of PEG on the mucosal hyper-proliferation, we
performed the immunohistochemical analysis of nuclear antigen Ki67, a well-defined marker of proliferation. A total of 1000 epithelial cells were
evaluated from 6–7 fields. As shown (bottom Panel; Figure 2A–B), 4NQO-treatment increased the proliferation in morphologically normal tongue
mucosa as depicted by increased number of Ki67-labelled epithelial cells/per optical field compared to age matched carcinogen free controls.
(p,0.01). Topical application of PEG on the other hand dramatically reduced the number of Ki67-labelled epithelial cells/per optical field (p,0.01).
doi:10.1371/journal.pone.0038047.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38047Figure 3. Effect of PEG-8000 on tongue mucosal EGFR and cyclin D1 expression in 4 NQO-treated rats –The tongue sections were
subjected to immunohistochemical analyses to assess changes in EGFR and Cyclin D1 expressions. As shown (left Panel - Figure 3A and
3B), baseline EGFR expression in the tongue mucosa of 4NQO-rats was higher than that of control rats (p,0.00001). Topical application of PEG
however, caused a significant decline in the expression of EGFR (p,0.005). Furthermore, topical PEG application to 4-NQO rats caused similar effects
on the expression of Cyclin D1, one of the downstream effectors of EGFR (right Panel - Figure 3A and 3B).
doi:10.1371/journal.pone.0038047.g003
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D1, a downstream effector of EGFR that is overexpressed in
HNSCC [21] and involved in causing resistance to therapeutic
drugs such as cisplatin [22] and gefitinib [23].
PEG Inhibits Cellular Proliferation and Induces Cell Cycle
Arrest in SCC-25 Cells
To understand the mechanism of PEG action on cellular
proliferation in HNSCC; we used an in vitro cell culture model
(squamous carcinoma cell line; SCC-25) to examine the effect of
PEG on proliferation and cell cycle distribution. As shown in
Figure 4A, the WST-1 proliferation assay revealed a dose
dependent decrease in the SCC-25 cell growth when treated with
PEG for 24 h, with maximal decrease of 43% obtained at 10%
PEG-8000. Therefore, for subsequent experiments 24 h treat-
ments of 10% PEG-8000 were utilized. The immunoblot results
demonstrated that PEG also caused , 50% decrease in
proliferation marker, PCNA (Figure 4B). Cell cycle arrest is one
of the important mechanisms of chemopreventive agents. To
investigate the effect of PEG-8000 on the cellular distribution we
performed flow cytometric analysis of PI labeled cells. Our results
show that 24 h treatment of SCC-25 cells with 10% PEG-8000
resulted in a marked reduction in S-phase (proliferative) cells (62%
of vehicle control; p,0.002) and a significant increase in G2-M
phase cells (138% of vehicle control; p,0.001) (Figure 4C). These
results clearly indicate that PEG treatment induces cell cycle arrest
in hyperproliferative cells, and could therefore help restore the
cellular homeostasis by modifying the altered rates of cancer cell
growth and death.
Treatment of SCC-25 Cells with PEG Decreases EGFR and
Cyclin D1 and Modulates the Expression of Cell Cycle
Regulatory Protein p21
cip1/waf1
From our in vivo 4NQO rat experiments, EGFR and Cyclin D1
were the two important targets downregulated by PEG; we wanted
to study if similar effects were observed in HNSCC cell lines. We
first performed immunoblot experiments to assess the expression
of EGFR and cyclin D1 upon 24 h treatment of PEG-8000 in
SCC25 cells. Consonant with the in vivo experiments we found that
treatment of SCC25 cells with PEG-8000 caused a significant
decrease EGFR (,45% compared to vehicle control; p,002) and
cyclin D1 (,57% compared to control vehicle; p,0.005)
expression (Figure 5 A). In PEG-induced colon cancer chemopre-
vention, we have previously shown that cell cycle arrest induced by
PEG-8000 implicates an EGFR-mediated upregulation of a cyclin-
dependent kinase inhibitor, p21
cip1/waf1 [24]. In a similar
experimental protocol, we found that PEG-8000 indeed caused
a ,54% increase in p21 expression (p,0.001) in SCC25 cells
(Figure 5B). Further studies are underway to characterize the
upstream pathways implicated in modulation of these cell cycle
regulators in SCC25 cells upon PEG treatment.
Discussion
We herein demonstrate, for the first time, that topical
application of PEG-8000 offered effective protection against oral
cancer development. Our cell culture data showing anti-prolifer-
ative effects of PEG in SCC-25 cells is complemented by the
decreased tumor burden in the well-validated 4-NQO-rat
HNSCC model (when given in the post-initiation phase). From
a mechanistic perspective, we demonstrate the downregulation of
EGFR with concomitant inhibition of the cyclin D1-proliferation
axis.
HNSCC should be eminently chemopreventable because the at-
risk groups are readily identifiable for both primary prevention
(tobacco chewing, alcohol, HPV etc) and secondary prevention.
This is because HNSCC patients with just a single primary tumor
have a significant risk of developing second primary tumors over
the next few decades. Also, patients with oral leukoplakia
(prevalence of ,0.5%) that engender a malignant transformation
rate of ,5% per year can benefit from this chemoprevention [25].
Thus, PEG for HNSCC prevention represents a potentially
clinically viable strategy.
In this regard, numerous chemopreventive agents, such as
NSAIDS [26], vitamin E [27] and retinoic acid [28] have been
tested against HNSCC but have failed due either to lack of efficacy
or toxicity [29]. For instance, a recent randomized phase II trial,
celecoxib at 100 or 200 mg twice daily was found to be ineffective
in controlling oral premalignant lesions and had significant
systemic toxicity such as cardiovascular side-effects [30]. Similarly,
retinoids were found to offer only modest protection against
development of SCC in leukoplakia patients, and with an
unacceptable side-effect profile [31]. The only other agent that
has shown encouraging results till to date has been green tea
extract (GTE), which, while failing to achieve statistical signifi-
cance in clinical response rate for oral premalignant lesions, still
increased the median length of progression (27.5 to 46.4 months)
[32].
The lack of compelling results with standard chemopreventive
agents has led to interest in utilizing a molecularly defined
candidate agent approach [33]. There have been two recent
comprehensive studies evaluating the mutational landscape of
HNSCC [34,35]. These studies revealed a number of genes that
are commonly altered in HNSCC. However, most of the putative
early events (e.g., p53 and NOTCH1) appear to be tumor
suppressor genes which are generally not ‘‘druggable’’ (inhibition
more likely to be beneficial for proto-oncogenes). Therefore, for
cancer prevention, not only do candidate targets need to be proto-
oncogenes but these lesions need to be diffusely present in the oral
mucosa of at-risk patients, especially in oral premalignant lesions
(OPLs; mainly comprising of leukoplakia). EGFR has been shown
to be a target in treatment of HNSCC with both monoclonal
antibodies and small molecule inhibitors as key components of the
therapeutic armamentarium. Besides, our data clearly demon-
strates a profound upregulation in EGFR in the histologically
normal oral/tongue mucosa in the 4NQO-treated rats. The
importance of EGFR in early carcinogenesis is emphasized by a
recent clinical trial which demonstrated that in most of the OPLs,
EGFR upregulation (both by copy number and expression)
correlated with high risk of progression to frank malignancy
[36,37]. From a chemopreventive perspective EGFR may be an
important target as revealed by the mechanistic evaluation of
green tea extract for cancer chemoprevention.
Our data indicates that PEG can cause a dramatic downreg-
ulation of EGFR both in cell culture and in the premalignant oral
mucosa, consistent with our extensive data of PEG in colorectal
carcinogenesis. Indeed, PEG is one of the most potent chemopre-
ventive agent against colorectal cancer [8,38]. The efficacy of PEG
in colon cancer has been supported by preliminary epidemiolog-
ical data [39]. From a mechanistic perspective, our laboratory has
previously demonstrated that EGFR was downregulated by PEG
in cell culture and in colon carcinogen (azoxymethane)-treated rat
model, [13]. This effect appeared to be via membrane internal-
ization with subsequent proteosomal degradation. The down-
stream consequences appear to follow the paradigm of EGFRRS-
NAILRE-CadherinRb-cateninRTcf transcriptional regulation
[13]. Importantly, the integral nature of EGFR was shown by
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the chemopreventive efficacy of PEG in this model of colon
cancer. Studies are currently ongoing to determine the exact
mechanism through which PEG internalizes EGFR. Furthermore,
consistent with our current data in HNSCC, we have previously
shown, in both cell culture and animal models of colon cancer,
that PEG-induced EGFR downregulation suppressed proliferation
potentially through cyclin D1. Furthermore, the G1RS phase cell
cycle arrest observed may be mediated, at least partly, through
induction of the p21
cip1/waf1, a cyclin dependent kinase inhibitor,
that may provide another modality of suppressing proliferation
[24]. Both cyclin D1 and loss of p21
cip1/waf1 have been shown to
mediate the antiproliferative activity of PEG in the colon, thereby
mirroring the current findings in oral cancer.
An important aspect to our HNSCC preventive strategy is the
topical delivery. One of the advantages of topical delivery is
decreased toxicity since there is little, if any, systemic toxicity
(swish/gargle and spit would avoid enteral absorption). While it
remains to be determined whether PEG delivered in this manner
can adequately cover all relevant areas (including pharyngeal
mucosa), topical chemopreventive agents have had some promise.
For instance, ketorolac tromethamine (a nonselective COX-
inhibitor) oral rinse has been shown to decrease oral prostaglan-
din, but not neoplasia [40]. Similarly, topical bioadhesive black
raspberry gel has been shown to modulate gene expression and
reduce cyclooxygenase 2 protein in human premalignant oral
lesions [41].
Though topical application of PEG may potentially represent a
significant advance in chemoprevention of HNSCC, there are
some questions that remain to be answered. Future studies will
need to answer several questions including the optimal PEG
formulation. We chose PEG 8000 for these studies based on data
to suggest that this was optimal molecular weight for colon
carcinogenesis. However, this will need to be confirmed and/or
Figure 4. Inhibition of cellular proliferation and induction of cell cycle arrest by PEG-8000 in SCC-25 cells- SCC-25 cells were treated
with different concentrations of PEG-8000 for 24 h and then assayed for proliferation using standard WST-1 assay. As shown
(Figure 4A), there was a dose dependent decrease in the cell growth, with maximal decrease of 43% obtained at 10% PEG-8000. Figure 4B shows a
,50% decrease on the expression of proliferation marker PCNA by PEG. Figure 4C shows the effect of PEG on cell cycle distribution. The 24 h PEG
treated cells were stained with propidium iodide and analyzed by flow cytometry. PEG blocked cells in the S-phase (by 62%) and correspondingly
increases the cells in G2-M phase (by 38%).
doi:10.1371/journal.pone.0038047.g004
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38047modified for HNSCC. We will need to determine PEG
formulation (concentration, viscosity etc) for better efficacy and
applicability. Finally, timing for introduction of PEG treatment
needs to be further assessed for achieving maximal effects. While
our studies with 4-NQO were performed at a relatively late stage,
this was done out of necessity to prevent confounding factors, since
both the carcinogen and PEG were given topically (possibly PEG
could block 4-NQO access to mucosa). Intervention earlier in
tumorigenesis is likely to show a greater benefit and can be
performed with other models of HNSCC (transgenic, orthotopic
etc).
There are a number of limitations of this study that need to be
acknowledged. First, our in vivo data was obtained from a well-
validated HNSCC model (4-NQO-treated rat) which may not
necessarily replicate the subset of human HNSCC that are related
to human papilloma virus (which harbor half the mutational load
of HPV negative tumors and a more muted EGFR upegulation)
[42]. Second, the role and mechanism of EGFR downregulation
in HNSCC remains to be fully determined. While we have
demonstrated that EGFR is critical in PEG mediated chemopre-
vention in colon carcinogenesis, the HNSCC link is simply by
analogy and requires further investigation. Furthermore, the
mechanism through which PEG induced EGFR endocytosis
requires elucidation in order to optimize PEG formulation.
In summary, we provide herein the proof of concept that topical
PEG may be an effective chemopreventive agent against HNSCC
using both cell culture and animal model. While the mechanisms
remains unclear, previous work related to colorectal cancer
suggests that PEG may work in HNSCC through targeting the
EGFRRproliferation axis, a critical event in HNSCC. Clinically,
the ability to topically prevent (via oral rinse, toothpaste, chewing
gum, lozenge etc) without toxicity may potentially represent a
major advance finally heralding an efficacious, cost-effective
cancer prevention strategy for HNSCC.
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